These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17201404)

  • 1. Discovery of aminofurazan-azabenzimidazoles as inhibitors of Rho-kinase with high kinase selectivity and antihypertensive activity.
    Stavenger RA; Cui H; Dowdell SE; Franz RG; Gaitanopoulos DE; Goodman KB; Hilfiker MA; Ivy RL; Leber JD; Marino JP; Oh HJ; Viet AQ; Xu W; Ye G; Zhang D; Zhao Y; Jolivette LJ; Head MS; Semus SF; Elkins PA; Kirkpatrick RB; Dul E; Khandekar SS; Yi T; Jung DK; Wright LL; Smith GK; Behm DJ; Doe CP; Bentley R; Chen ZX; Hu E; Lee D
    J Med Chem; 2007 Jan; 50(1):2-5. PubMed ID: 17201404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors.
    Goodman KB; Cui H; Dowdell SE; Gaitanopoulos DE; Ivy RL; Sehon CA; Stavenger RA; Wang GZ; Viet AQ; Xu W; Ye G; Semus SF; Evans C; Fries HE; Jolivette LJ; Kirkpatrick RB; Dul E; Khandekar SS; Yi T; Jung DK; Wright LL; Smith GK; Behm DJ; Bentley R; Doe CP; Hu E; Lee D
    J Med Chem; 2007 Jan; 50(1):6-9. PubMed ID: 17201405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities.
    Doe C; Bentley R; Behm DJ; Lafferty R; Stavenger R; Jung D; Bamford M; Panchal T; Grygielko E; Wright LL; Smith GK; Chen Z; Webb C; Khandekar S; Yi T; Kirkpatrick R; Dul E; Jolivette L; Marino JP; Willette R; Lee D; Hu E
    J Pharmacol Exp Ther; 2007 Jan; 320(1):89-98. PubMed ID: 17018693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rho-kinase inhibitor may exert a role in preventing cardiac hypertrophy, independent of antihypertensive effects.
    Pan M; Jing HM; Zhu JH; Liu ZH; Jiang WP; Yang XJ
    Med Hypotheses; 2007; 68(1):234. PubMed ID: 16919397
    [No Abstract]   [Full Text] [Related]  

  • 5. Rho-kinase as a potential therapeutic target for the treatment of pulmonary hypertension.
    Xing XQ; Gan Y; Wu SJ; Chen P; Zhou R; Xiang XD
    Drug News Perspect; 2006 Nov; 19(9):517-22. PubMed ID: 17220956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors.
    Fang X; Yin Y; Chen YT; Yao L; Wang B; Cameron MD; Lin L; Khan S; Ruiz C; Schröter T; Grant W; Weiser A; Pocas J; Pachori A; Schürer S; Lograsso P; Feng Y
    J Med Chem; 2010 Aug; 53(15):5727-37. PubMed ID: 20684608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rho kinase inhibitors as potential therapeutic agents for cardiovascular diseases.
    Hu E; Lee D
    Curr Opin Investig Drugs; 2003 Sep; 4(9):1065-75. PubMed ID: 14582450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of Rho kinase inhibitors (I).
    Takami A; Iwakubo M; Okada Y; Kawata T; Odai H; Takahashi N; Shindo K; Kimura K; Tagami Y; Miyake M; Fukushima K; Inagaki M; Amano M; Kaibuchi K; Iijima H
    Bioorg Med Chem; 2004 May; 12(9):2115-37. PubMed ID: 15080913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of Rho kinase inhibitors (II).
    Iwakubo M; Takami A; Okada Y; Kawata T; Tagami Y; Ohashi H; Sato M; Sugiyama T; Fukushima K; Iijima H
    Bioorg Med Chem; 2007 Jan; 15(1):350-64. PubMed ID: 17046269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-(Benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: potent and selective p70S6 kinase inhibitors.
    Bandarage U; Hare B; Parsons J; Pham L; Marhefka C; Bemis G; Tang Q; Moody CS; Rodems S; Shah S; Adams C; Bravo J; Charonnet E; Savic V; Come JH; Green J
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5191-4. PubMed ID: 19632115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of rho kinase inhibitors (III).
    Iwakubo M; Takami A; Okada Y; Kawata T; Tagami Y; Sato M; Sugiyama T; Fukushima K; Taya S; Amano M; Kaibuchi K; Iijima H
    Bioorg Med Chem; 2007 Jan; 15(2):1022-33. PubMed ID: 17084087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Rho and Rho-kinase in the treatment of cardiovascular disease.
    Budzyn K; Marley PD; Sobey CG
    Trends Pharmacol Sci; 2006 Feb; 27(2):97-104. PubMed ID: 16376997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linking phenotype to kinase: identification of a novel benzoxaborole hinge-binding motif for kinase inhibition and development of high-potency rho kinase inhibitors.
    Akama T; Dong C; Virtucio C; Sullivan D; Zhou Y; Zhang YK; Rock F; Freund Y; Liu L; Bu W; Wu A; Fan XQ; Jarnagin K
    J Pharmacol Exp Ther; 2013 Dec; 347(3):615-25. PubMed ID: 24049062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4.
    Powers JP; Li S; Jaen JC; Liu J; Walker NP; Wang Z; Wesche H
    Bioorg Med Chem Lett; 2006 Jun; 16(11):2842-5. PubMed ID: 16563752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rho kinase: a target for treating urinary bladder dysfunction?
    Peters SL; Schmidt M; Michel MC
    Trends Pharmacol Sci; 2006 Sep; 27(9):492-7. PubMed ID: 16870270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of 2-arylthieno[3,2-d]pyrimidines containing 8-oxa-3-azabi-cyclo[3.2.1]octane in the 4-position as potent inhibitors of mTOR with selectivity over PI3K.
    Verheijen JC; Yu K; Toral-Barza L; Hollander I; Zask A
    Bioorg Med Chem Lett; 2010 Jan; 20(1):375-9. PubMed ID: 19897362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rho-kinase inhibition suppresses potassium chloride-induced bladder hyperactivity in a rat model.
    Rajasekaran M; Mehta N; Baquir A; Kuntz S
    Urology; 2007 Apr; 69(4):791-4. PubMed ID: 17445683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of 6-aryl-azabenzimidazoles that inhibit the TBK1/IKK-ε kinases.
    Johannes JW; Chuaqui C; Cowen S; Devereaux E; Gingipalli L; Molina A; Wang T; Whitston D; Wu X; Zhang HJ; Zinda M
    Bioorg Med Chem Lett; 2014 Feb; 24(4):1138-43. PubMed ID: 24462666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triazine and pyrimidine based ROCK inhibitors with efficacy in spontaneous hypertensive rat model.
    Ho KK; Beasley JR; Belanger L; Black D; Chan JH; Dunn D; Hu B; Klon A; Kultgen SG; Ohlmeyer M; Parlato SM; Ray PC; Pham Q; Rong Y; Roughton AL; Walker TL; Wright J; Xu K; Xu Y; Zhang L; Webb M
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6027-31. PubMed ID: 19800787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization.
    Harris CM; Ericsson AM; Argiriadi MA; Barberis C; Borhani DW; Burchat A; Calderwood DJ; Cunha GA; Dixon RW; Frank KE; Johnson EF; Kamens J; Kwak S; Li B; Mullen KD; Perron DC; Wang L; Wishart N; Wu X; Zhang X; Zmetra TR; Talanian RV
    Bioorg Med Chem Lett; 2010 Jan; 20(1):334-7. PubMed ID: 19926477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.